Cancer Res:前列腺癌风险新的易感位点和基因鉴定

2019-05-30 AlexYang MedSci原创

全基因组关联研究鉴定了与前列腺癌风险相关的遗传变异位点。然而,这些变异只能解释一部分前列腺癌的风险的遗传组成,并且那些与前列腺癌风险相关的基因还没有完全鉴定。最近,有研究人员为了发现新的前列腺癌遗传位点和之前已经鉴定位点的可能的发病基因,研究人员在具有欧洲血统的79194个案例和61112个对照中进行了全基因组关联分析。研究发现,他们在137个基因中发现的显著的相关性(P<2.61×10-6

全基因组关联研究鉴定了与前列腺癌风险相关的遗传变异位点。然而,这些变异只能解释一部分前列腺癌的风险的遗传组成,并且那些与前列腺癌风险相关的基因还没有完全鉴定。最近,有研究人员为了发现新的前列腺癌遗传位点和之前已经鉴定位点的可能的发病基因,研究人员在具有欧洲血统的79194个案例和61112个对照中进行了全基因组关联分析。

研究发现,他们在137个基因中发现的显著的相关性(P<2.61×10-6),在调整了所有已知的前列腺癌风险变异之后,仍旧有9个基因保持显著的相关性(P<2.61×10-6)。在剩下的128个相关基因中,94个处于已知的位点,但是属于未报道的靶基因。研究人员沉默了14个基因,其中许多基因在三种细胞系中表现出了一致的存活率和集落形成效率。

最后,研究人员指出,他们的研究为进一步理解前列腺癌的遗传和生物学提供了新的信息。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022579, encodeId=873620225e9e4, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Tue Jun 11 12:49:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019026, encodeId=4a0e201902696, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Wed Nov 27 21:49:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061849, encodeId=2db92061849ad, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Apr 15 11:49:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040467, encodeId=a79d104046e09, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 30 15:49:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022579, encodeId=873620225e9e4, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Tue Jun 11 12:49:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019026, encodeId=4a0e201902696, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Wed Nov 27 21:49:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061849, encodeId=2db92061849ad, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Apr 15 11:49:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040467, encodeId=a79d104046e09, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 30 15:49:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022579, encodeId=873620225e9e4, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Tue Jun 11 12:49:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019026, encodeId=4a0e201902696, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Wed Nov 27 21:49:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061849, encodeId=2db92061849ad, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Apr 15 11:49:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040467, encodeId=a79d104046e09, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 30 15:49:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
    2020-04-15 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022579, encodeId=873620225e9e4, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Tue Jun 11 12:49:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019026, encodeId=4a0e201902696, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Wed Nov 27 21:49:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061849, encodeId=2db92061849ad, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Apr 15 11:49:00 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040467, encodeId=a79d104046e09, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu May 30 15:49:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
    2019-05-30 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Brit J Cancer:基于CE-MS的尿液生物标记可以区分显著性前列腺癌和非显著性前列腺癌

低风险前列腺癌的恶化较为缓慢,但是当发展为转移性疾病时则是致死的。因此,一种能够检测显著性前列腺癌的非侵入测试方法是需要的,从而来指导患者的治疗。毛细管电影/质谱可以用来鉴定尿液中的多肽,这些多肽也许能够准确的检测显著性前列腺癌。研究人员在823名患者(PSA<15ng/ml)活检前收集了尿液样本,并在包含543名(nSig=98; nnon-Sig=445)患者的训练集和280名患者的鉴定

盘点:前列腺癌与治疗小结

【1】Prostate Cancer P D:前列腺癌中质子放射治疗与光子放射治疗比较 https://www.nature.com/articles/s41391-019-0140-7放射技术的进展改变了局部前列腺癌患者的治疗选择。三维适形放射治疗和可调节强度放射治疗(IMRT)使得医生可以避免邻近正常组织受放射影响,从而减少副作用事件。质子束技术的引入及其在病理组织中能量具有最大范围的物理

盘点:前列腺癌相关机制小结

【1】Sci Rep:前列腺癌细胞中Skp2的高表达与间叶细胞表型和致瘤潜能的增加相关 https://www.nature.com/articles/s41598-019-42131-ySkp2是SCFSkp2E3泛素连接酶的关键组分,并且在各种类型的癌症中均过表达,包括了前列腺癌(PCa)。上皮间质转化(EMT)与PCa的恶化相关。最近,有研究人员基于PCa中间叶细胞表型的获得能够导致癌症

Sci Rep:前列腺癌中H&E和IHC染色组织病理样本比色分析的特征图研究

前列腺癌(PCa)是男性癌症死亡的主要诱因。术后前列腺样本的组织病理学检查和PCa的人工注释不仅为疾病特性和程度提供详细的评估,也为确定性治疗之前PCa检测的计算机辅助诊断(CAD)系统开发提供了坚实的基础。由于人工注释枯燥且具有主观性,已经有很多的研究阐释了通过对成像分析实现自动化的方法。然而,这些研究只关注了苏木精和伊红(H&E)染色成像分析,而忽略了从免疫组化(IHC)染色中获得的额

前列腺癌治还是不治?染色体可以告诉你答案

治疗还是不治疗?对于前列腺癌患者和医生来说,这仍是一个棘手的问题。因为一些肿瘤可能极具侵略性,而另一些则比较“温和”,可能要几十年才会造成伤害。

Iran Biomed J:新型聚腺苷二磷酸核糖聚合酶(RARP)抑制剂AZD2461能够下调VEGF表达和诱导前列腺癌细胞凋亡

前列腺癌(PCa)是一种异质性疾病,目前的治疗手段并不是基于分子层面。最近有报道表明,RARP抑制剂对具有同源重组缺陷的细胞具有明显的毒性,尤其是那些BRCA变异背景的细胞。因此,最近有研究人员评估了是否PTEN表达状态对侵入性PCa细胞对RARP抑制剂AZD2461的敏感性具有影响。研究发现,MTT结果表明了AZD2461对PC-3细胞的抑制作用要比DU145细胞显著更高(处理后48小时的IC5